Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 11, Number 8—August 2005


Cost-Benefit of Stockpiling Drugs for Influenza Pandemic

Ran D. Balicer*†Comments to Author , Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†
Author affiliations: *Ministry of Health, Jerusalem, Israel; †Ben-Gurion University of the Negev, Be'er-Sheva, Israel

Main Article

Table A3

Neuraminidase efficacy and related parameters included in the model

Variable Point estimate Range Reference
Efficacy of antiviral prophylaxis*
Preexposure prophylaxis† 71 57–85 24,28
Postexposure prophylaxis† 36 25–47 29
Efficacy of antiviral therapy
% reduction in hospitalization 59 30–70 27
% reduction in antimicrobial drug use 63 40–80 26
Reduction in lost work days under treatment 1 0.5–1.5 26
Annual probability of pandemic (%) 3 1–10 Assumed
% patients seeking medical care within 48 hours 80 70–90 16

*Efficacy presented as percent reduction of attack rate.
†Based on a meta-analysis of 2 studies (see text for details).

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO